Peripheral blood T cell alterations and their prognostic role in newly diagnosed primary central nervous system lymphoma - PNCLS

niversitätsklinik für Hämatologie und Onkologie0 个研究点目标入组 90 人开始时间: 2021年5月3日最近更新: 2024年8月19日

试验速览

暂无简介。

•1. Immunocompetent patients with newly diagnosed PZNSL =18 years
•- Histologically confirmed diagnosis of DLBCL according to WHO by a local pathologist
•- Chemotherapy-eligible patients
•2. Immunocompetent patients with newly diagnosed nodal DLBCL =18 years of age
•- Histologically confirmed diagnosis of DLBCL according to WHO by a local pathologist
•- Chemotherapy-eligible patients
•3. Healthy volunteers =18 years of age
•Written informed consent from patients and healthy volunteers or authorized legal carers in the event that the patient or volunteer is unable to provide information

•- Congenital or acquired immune deficiencies, including HIV infection and previous organ or stem cell transplantation
•- Lymphoma manifestation outside the central nervous system
•- Congenital or acquired immune deficiencies, including HIV infection and previous organ transplants
•- Congenital or acquired immune deficiencies, including HIV infection and previous organ or stem cell transplantation
•- Acute infection or illness in the last 4 weeks (e.g. heart attack, broken bone, surgery, etc.)
•- Known chronic infection (e.g. hepatitis B / C etc.)
•- Known malignancy, with the exception of one that was treated with curative intent and had no evidence of active disease for> 2 years prior to the start of the study
•- Known autoimmune disease
•- Pregnant or breastfeeding participants

发起方

niversitätsklinik für Hämatologie und Onkologie